Articles From: Sandvine reports Q2 2014 results to Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014


Sandvine reports Q2 2014 results Canada NewsWire WATERLOO, ON , July 10, 2014 /CNW/ - Sandvine , (TSX:SVC) a leading provider of intelligent network policy control solutions for fixed and mobile operators, today reported revenue of $29.7 million for its second quarter of 2014, net income of $4.4 million and non-IFRS income of $4.8 million .
Sign-up for Sandvine reports Q2 2014 results investment picks
Sandvine sets date for release of Q2 2014 results Canada NewsWire WATERLOO, ON , June 26, 2014 /CNW/ - Sandvine , (TSX:SVC) a leading provider of intelligent broadband network solutions for fixed and mobile operators, will release its second quarter 2014 financial results on July 10, 2014 before markets open in North America .
Sign-up for Sandvine sets date for release of Q2 2014 results investment picks
Sandvine's board approves plan for stock buyback program Canada NewsWire WATERLOO, ON , Sept.
Sign-up for Sandvine's board approves plan for stock buyback program investment picks
Sandvine's Managed Business Services Wins Award for Virtualization at Intel® Developers Forum Canada NewsWire WATERLOO, ON , Sept.
Sign-up for Sandvine's Managed Business Services Wins Award for Virtualization at Intel® Developers Forum investment picks
OLNEY, Md., July 31, 2014 (GLOBE NEWSWIRE) -- Sandy Spring Bancorp, Inc., (Nasdaq:SASR) , the parent company of Sandy Spring Bank, announced that the board of directors declared a quarterly common stock dividend of $0.20 per share payable on August 20, 2014 to shareholders of record on August 13, 2014.
Sign-up for Sandy Spring Bancorp Increases Dividend to $0.20 Per Share investment picks
OLNEY, Md., July 17, 2014 (GLOBE NEWSWIRE) -- Sandy Spring Bancorp, Inc., (Nasdaq:SASR) the parent company of Sandy Spring Bank, today reported net income for the second quarter of 2014 of $7.0 million ($0.28 per diluted share) compared to net income of $12.2 million ($0.49 per diluted share) for the second quarter of 2013 and net income of $10.9 million ($0.43 per diluted share) for the first quarter of 2014.
Sign-up for Sandy Spring Bancorp Reports Net Income of $7.0 Million for the Second Quarter investment picks
OLNEY, Md., July 3, 2014 (GLOBE NEWSWIRE) -- Sandy Spring Bancorp, Inc. (Nasdaq:SASR) will announce its 2nd quarter earnings on Thursday, July 17, 2014.
Sign-up for Sandy Spring Bancorp, Inc. to Webcast 2nd Quarter Earnings Conference Call on July 17, 2014 investment picks
OLNEY, Md., July 24, 2014 (GLOBE NEWSWIRE) -- Sandy Spring Bank (Nasdaq:SASR) has announced the appointment of George Cave as Senior Vice President and Commercial Banking Division Leader.
Sign-up for Sandy Spring Bank Appoints George Cave as Senior Vice President and Northern Virginia Market Leader investment picks
2014/6/24
Sanford Health, the largest rural, not-for-profit health care system in the United States, and GE Healthcare , a division of General Electric Company (NYSE: GE), today announced a 10-year comprehensive service agreement that will enable Sanford to focus on its expanding healthcare capabilities while GE Healthcare drives efficient, standardized operations across Sanford’s growing network.
Sign-up for Sanford Health Engages GE Healthcare to Deliver $44.6 Million in Operational Savings over 10 Years investment picks
Control of Viral Load During Treatment Interruption of Antiretroviral Therapy Sustained and Ongoing for More than One Year in One Subject and Several Months in Another Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T RICHMOND, Calif.
Sign-up for Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV-Infected Subjects Treated with SB-728-T investment picks
RICHMOND, Calif.
Sign-up for Sangamo BioSciences Announces Second Quarter 2014 Conference Call And Webcast investment picks
Timeline for Hemophilia B IND Application Filing Targeting Second Quarter 2015 RICHMOND, Calif.
Sign-up for Sangamo BioSciences Announces Target Date For First IND For Sangamo's In Vivo ZFN Genome-Editing Platform For Monogenic Diseases investment picks
RICHMOND, Calif.
Sign-up for Sangamo BioSciences Appoints H. Stewart Parker to its Board of Directors investment picks
RICHMOND, Calif.
Sign-up for Sangamo BioSciences Reports Second Quarter 2014 Financial Results investment picks
Together with Excellence Cluster Cardio-Pulmonary System (ECCPS) and TransMIT Gesellschaft für Technologietransfer mbH (TransMIT), Sangui is investigating new therapeutic approaches to treating septic shock and acute respiratory distress syndrome (ARDS). Owing to their incidence rate, complexity and poor prognosis, the two diseases constitute a huge challenge in both in terms of their socio-economic impact and the associated intensive medical care, and incur unacceptably high mortality rates, despite progress made in intensive medicine.
Sign-up for Sangui BioTech: Start of preclinical trials investment picks
2014/7/29
According to preliminary, unaudited figures Sangui Biotech International, Inc. yielded revenues from royalties and product sales of USD42,000 in the course of the fourth quarter of its financial year 2014, ended June 30, 2014.
Sign-up for SanguiBioTech yields revenues of around USD42,000 in Q4 2014 according to preliminary figures investment picks
2014/7/28
Sankaty Advisors, LLC, the independently managed credit affiliate of Bain Capital, today announced the signing of a definitive agreement to acquire a portfolio of loans and other securities from J.P. Morgan’s Global Special Opportunities Group.
Sign-up for Sankaty Advisors Acquires J.P. Morgan's Global Special Opportunities Group Investment Portfolio investment picks
2014/7/21
SAN JOSE, Calif.
Sign-up for Sanmina Reports Third Quarter Fiscal 2014 Results investment picks
NEW YORK (MarketWatch) -- Shares of Sanmina-SCI (SANM) ran up 8.3% in after-hours trade Monday after the electronics contract manufacturer reported better-than-expected fiscal third-quarter results and provided an upbeat outlook for the current quarter.
Sign-up for Sanmina-SCI shares soar in after-hours trade as earnings, revenue beat estimates investment picks
InnerWorkings, Inc. (NASDAQ: INWK) a leading global marketing supply chain company, has been selected as a global marketing partner of Sanofi, one of the world’s most well-known healthcare companies.
Sign-up for Sanofi and InnerWorkings Sign Global Marketing Partnership investment picks
PARIS and VALENCIA, Calif., Aug.
Sign-up for Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin investment picks
PARIS and MINNEAPOLIS, June 14, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT:SAN) (NYSE:SNY) and Medtronic, Inc. (NYSE:MDT) today announced that they have signed a memorandum of understanding to enter into a global strategic alliance in diabetes, aimed at improving patient experience and outcomes for people with diabetes around the world.
Sign-up for Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes investment picks
PARIS and TARRYTOWN, N.Y., July 9, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.
Sign-up for Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis investment picks
- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y. , Aug.
Sign-up for Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Sandvine reports Q2 2014 results to Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices